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Background: ZFP36, also known as tristetraprolin or TTP, and ELAVL1, also known as HuR, are two disease-relevant
RNA-binding proteins (RBPs) that both interact with AU-rich sequences but have antagonistic roles. While ELAVL1
binding has been profiled in several studies, the precise in vivo binding specificity of ZFP36 has not been
investigated on a global scale. We determined ZFP36 binding preferences using cross-linking and
immunoprecipitation in human embryonic kidney cells, and examined the combinatorial regulation of AU-rich
elements by ZFP36 and ELAVL1.
Results: Targets bound and negatively regulated by ZFP36 include transcripts encoding proteins necessary for
immune function and cancer, and transcripts encoding other RBPs. Using partial correlation analysis, we were able
to quantify the association between ZFP36 binding sites and differential target RNA abundance upon ZFP36
overexpression independent of effects from confounding features. Genes with increased mRNA half-lives in ZFP36
knockout versus wild-type mouse cells were significantly enriched for our human ZFP36 targets. We identified
thousands of overlapping ZFP36 and ELAVL1 binding sites, in 1,313 genes, and found that ZFP36 degrades
transcripts through specific AU-rich sequences, representing a subset of the U-rich sequences ELAVL1 interacts
with to stabilize transcripts.
Conclusions: ZFP36-RNA target specificities in vivo are quantitatively similar to previously reported in vitro binding
affinities. ZFP36 and ELAVL1 bind an overlapping spectrum of RNA sequences, yet with differential relative
preferences that dictate combinatorial regulatory potential. Our findings and methodology delineate an approach
to unravel in vivo combinatorial regulation by RNA-binding proteins.Background
Regulation of gene expression is a complex process
coordinated at many steps. Post-transcriptional regula-
tion is controlled through RNA-binding proteins (RBPs)
and non-coding RNAs (ncRNAs) interacting with RNA
regulatory elements (RREs). Dynamic and combinatorial
interactions of RBPs and ncRNAs with these RREs deter-
mine the functional outcome of specific steps of RNA
processing, such as splicing, polyadenylation, export, sta-
bility and translation [1]. Additionally, interactions be-
tween RBPs and RREs govern messenger RNA (mRNA)
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reproduction in any medium, provided the orAU-rich elements (AREs) are conserved cis-regulatory
elements, originally discovered in the 3′ untranslated re-
gion (UTR) of labile mRNAs, encoding cytokines and
early expressed immune response genes [2,3]. The most
commonly defined AREs are the pentamer AUUUA,
which is often found tandemly arranged, and the nonamer
UUAUUUAUU, which is a pentamer flanked by uridylates
[4-6]. AREs are generally considered instability elements,
since they typically interact with RBPs that subsequently
recruit mRNA degradation machinery [7,8]. Examples of
ARE-binding proteins include the ELAV family, ZPF36
family, HNRNPD/AUF family, TIA1, TIAR and KSRP.
Mice lacking the AU-rich region containing multiple AREs
residing in the 3′ UTR of the tumor necrosis factor α
(TNFα) transcript develop inflammatory disease, demon-
strating their primacy in gene regulatory mechanisms [9].tral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TIS11 family of RBPs. It interacts with AREs through
tandem CCCH zinc fingers (TZFs) [10]. Mice deficient
in ZFP36 also exhibit inflammatory disease phenotypes,
mostly explained by deregulation of TNFα mRNA stabil-
ity and biosynthesis [11]. The interaction of ZFP36 with
AREs in the 3′ UTR of targeted mRNAs, such as TNFα,
promotes mRNA degradation [12]. ZFP36 is a nucleo-
cytoplasmic shuttling protein that is predominantly cyto-
plasmic at steady state [13]. The RNA-binding specificity
of ZFP36 resides in the TZF domain, which interact with
low nanomolar affinity with synthetic RNA substrates
containing the nonamer UUAUUUAUU [14]. The NMR
structure of the nonamer sequence bound to the TZF
domain from human ZFP36L2 revealed that the zinc
fingers symmetrically bind to UAUU half-sites, with the
5′ uridylate unbound [15]. There have been many de-
tailed in vitro investigations of ZFP36–mRNA inter-
action (reviewed in [16]); however, in vivo studies have
only determined the mRNA pools associated with ZFP36
and have not defined individual binding sites at high
resolution [17,18].
Although many ARE-binding RBPs recruit mRNA
degradation complexes, the ELAV/Hu family of proteins
binds to AREs and promotes mRNA stability and trans-
lation [2,3,19-21]. Both in vitro and in vivo studies have
determined that Hu proteins interact with AREs, as well
as U and CU-rich sequences [4-6,22,23]. These sequence
preferences were substantiated in vivo using photoacti-
vatable ribonucleoside cross-linking and immunoprecipi-
tation (PAR-CLIP) to define high-resolution interaction
sites for the ubiquitously expressed family member
ELAVL1 [7,8,24-26]. Due to T-to-C transitions indicative
of RBP–RNA interaction sites [10,27], PAR-CLIP gives a
higher resolution of binding sites than earlier methods
[11,28,29]. A commonly postulated mechanism through
which ELAVL1 promotes mRNA stability is competition
with ARE-binding RBPs that promote degradation. Like
ZFP36, ELAVL1 is a nucleo-cytoplasmic shuttling pro-
tein, but under normal conditions is predominantly
nuclear localized [12,30], consistent with numerous in-
tronic binding sites found in PAR-CLIP experiments
[13,24-26]. Simultaneous temporal and spatial competi-
tion for binding sites by ELAVL1 and ZFP36 is import-
ant when responding to stimuli, particularly immune
activation, upon which ELAVL1 redistributes from the
nucleus to the cytoplasm [14,31] and ZFP36 is induced
and cytoplasmically localized. There is evidence for com-
petitive binding and displacement of ZFP36 with in-
creasing amounts of ELAVL1 and/or MAPK signaling
influencing the combinatorial regulation of the TNFα
mRNA by ELAVL1 and ZFP36 [15,32]. However, the ex-
tent to which similar competitive mechanisms exist
transcriptome-wide is unknown.Conflated direct and indirect relations are a concern, par-
ticularly when integrating multiple genomic measurements
to understand complex gene regulatory mechanisms. An
example of a relation relevant for post-transcriptional regu-
lation is that longer transcripts contain more binding sites
for trans-acting factors. Consequently, significant correla-
tions between 3′ UTR length and miRNA-dependent
downregulation have been found in numerous datasets
[16,33]. Overexpression of ZFP36 in the absence of stress
has been demonstrated to promote stress granule assembly
[18], potentially causing non-ZFP36 specific effects in tran-
script abundance. Partial correlation analysis quantifies the
direct dependence between two variables (for example,
number of binding sites or expression changes) when ac-
counting for other variables (for example, UTR length and
mRNA abundance). It has recently been applied to investi-
gate genome evolution [34,35], as well as chromatin state
and transcriptional regulation [36]. Here we apply it to ac-
count for generic transcript features when inferring func-
tional relations between the number of binding sites and
gene expression changes due to perturbing the expression
of the RBP.
There are numerous examples of combinatorial binding
of RBPs resulting in specific splicing decisions [37-40], but
this has not been as extensively studied for mRNA stabil-
ity. Given the numerous ARE-binding RBPs, the principles
underlying the integration of RBP binding and concomi-
tant regulatory outcomes have remained elusive. We there-
fore determined the in vivo mRNA-binding sites of ZFP36.
The interaction sites and sequence preferences were com-
pared to similarly acquired in vivo HuR interaction data,
specifically contrasting AU-rich sequences with predomin-
antly U- and CU-rich sequences. Our results indicate
active competition between ZFP36 and ELAVL1 for com-
monly used AU-rich sequences and define the characteris-
tics of these combinatorial regulatory events.
Results and discussion
ZFP36 preferentially binds to 3′ UTRs of mRNAs encoding
regulators of gene expression
We employed PAR-CLIP to identify the in vivo ZFP36
binding sites transcriptome-wide in human embryonic
kidney cells (HEK293) [41]. We chose HEK293 cells and
FLAG/HA-tagged ZFP36 to be as consistent as possible
with previous relevant PAR-CLIP experiments with
other RBPs, specifically ELAVL1. Ribonuclease-treated,
immunoprecipitated and radiolabeled ribonucleoprotein
(RNP) complexes resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) revealed
a major band at approximately 50 kDa corresponding
to the FLAG/HA-tagged ZFP36 (Figure 1A). The cDNA
sequence reads were processed and aligned to the hu-
man genome (see Materials and methods and Additional
file 1 for detailed parameters). PARalyzer, an algorithm
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Figure 1 ZFP36 RNA binding site characteristics. (A) Phosphor image of the SDS-PAGE fractionating of the PAR-CLIP immunoprecipitate from
doxycycline-induced FLAG/HA-tagged ZFP36 and IGF2BP1 (specificity control) HEK293 cells. (B) Length distribution of ZFP36 mRNA binding sites.
(C) Proportion of binding sites mapping to different mRNA regions. (D) ZFP36 site distribution in 3′ UTRs (red line). Median (black), interquartile
range (dark blue), interdecile range (light blue) and the outliers (grey lines) are shown for the background. (E) Over-representation of ZFP36
sites (red line) at the distal end of 3′ UTRs relative to the background. (F) Proportion of genes with specific regions of ZFP36 binding sites. nt,
nucleotide; PAR-CLIP, photoactivatable ribonucleoside cross-linking and immunoprecipitation; St Dev, standard deviation; UTR, untranslated region;
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
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of RBP–RNA interactions, distinguished 4,626 clus-
ters genome-wide (also referred to as binding sites,
Additional file 2: Table S1) with a mean length of 25
nucleotides from 328,433 uniquely aligned T-to-C rec-
onciled reads (Figure 1B and Additional file 3: Figure
S1A) [42]. Of the binding sites mapping to annotated
and repeat-masked sequences (3,497), those located in
mRNA accounted for 94% (3,289).
The majority of ZFP36 mRNA binding sites (70%,
2,314) mapped to the 3′ UTR, and very few binding sites
were located at the 5′ UTR or the protein coding region
(Figure 1C). Approximately one-quarter of the mRNA
binding sites were intronic (871), which is conceivable
since ZFP36 is a known nucleo-cytoplasmic shuttling
RBP [13]. However, the 3′ UTR sites had a substantially
higher T-to-C conversion fraction and specificity rela-
tive to ZFP36 sites from other annotation categories in-
cluding introns, 5′ UTRs and protein coding regions
(Additional file 3: Figure S1B). We observed closely
spaced ZFP36 sites within 3′ UTRs (Figure 1D), indica-
tive of multimerization of ZFP36 and supported by re-
sults from 2-hybrid analysis and immunoreactive bands
migrating at twice the expected number of kilodaltons of
ZFP36 in cell extracts (PJB, unpublished data). Of the
1,148 transcripts with more than one ZFP36 site in the
3′ UTR, 228 had two sites within 70 nucleotides, the
range for which proximity of ZFP36 sites is above back-
ground. The statistically significant enrichment for
ZFP36 sites in the last 100 nucleotides of the 3′ UTR
(Figure 1E) was intriguing given its ability to promote
deadenylation [43]. This spatial bias was not observed
for the sites of all other investigated 3′ UTR binding
RBPs (Additional file 3: Figure S1D) and thus not due to
biases in library generation, though it may be related to
AU-richness proximal to polyadenylation sites [44]. Of
the 2,143 genes with ZFP36 sites, 64% exclusively had
3′ UTR sites, 23% exclusively had intronic sites and only
8% contained both 3′ UTR and intronic sites (Figure 1F).
Genes with 3′ UTR sites were less likely to also have
intronic sites in contrast to ELAVL1 [25]. The strong
preference for 3′ UTR binding was anticipated for an
RBP predominantly involved in cytoplasmic regulation
of mRNA stability and translation.
ZFP36 sites were found to be significantly enriched in
transcripts encoding transcriptional and post-transcriptional
regulatory proteins (Figure 2A). In addition to its own
3′ UTR (Figure 2B,C), we detected ZFP36 binding to nu-
merous sites within the 3′ UTR of several other RBPs ne-
cessary for proper immune function [11,45-47], including
ZFP36 family members ZFP36L1 and ZFP36L2 (five sites
each; Figure 2B,D,E), ELAVL1 (two sites; Figure 2B,F),
as well as RC3H1 and RC3H2 (two and three sites, re-
spectively; Figure 2B). We also found that most of theZFP36 sites in these 3′ UTRs overlapped with ELAVL1
sites (Figure 2B). The similarity of the binding domain
and sequence specificity of other ZFP36 family mem-
bers and the presence of both ZFP36 and ELAVL1
binding sites in these 3′ UTRs warrant future investiga-
tion as a network motif that could potentially produce in-
teresting temporal expression patterns, particularly in the
context of stimuli inducing ZFP36 protein expression.
In vivo ZFP36 binding specificity
Since de novo motif finding in PARalyzer-defined ZFP36
binding sites confirmed AU-rich sequences as the most
highly enriched sequence motifs (data not shown), we
utilized the wealth of detailed in vitro experimental
evidence for ZFP36 RNA substrate specificity (reviewed
in [16]) to guide more detailed analyses. More than 84%
of the mRNA sites contained known ZFP36 RREs: the
classic nonamer UUAUUUAUU (8%), the octamer
UAUUUAUU (14%) identified as the residues contacted
by the TZF domain in the TIS11D structure, a single
UAUU half-site (82%), or the AUUUA pentamer (47%).
A similar fraction of intronic ZFP36 sites (804 of 871)
contained one or more of the above RREs, indicating
their potential for functional relevance. To assess the en-
richment of each individual RRE we calculated a signal-
to-noise ratio (SNR). This reflects the rate of occurrence
of a specific sequence in ZFP36 sites relative to the ex-
pected rate of occurrence in the background sequence,
in this case within 3′ UTRs (see Materials and methods
for details). Each of the above RREs were found 40 to
250 times more often in the ZFP36 sites than expected
by chance and were at least twice as enriched as polyU-
stretches of the same respective length (Figure 3A).
Since the ELAVL1 library was sequenced at higher depth
than the ZFP36 library, we used a size-matched subset
of the ELAVL1 library using the top sites by read count
(ELAVL1best) to compare SNR values of various U-rich
pentamer sequences in the ZFP36 to ELAVL1 PAR-CLIP
data (Additional file 3: Figure S1C). The AUUUA penta-
mer was relatively more enriched in the ZFP36 sites,
whereas UUUUU and U-stretches flanked by C on both
or either end were relatively more enriched in ELAVL1
sites (Figure 3B). These contrasting sequence preferences
are consistent with highly quantitative in vitro binding
studies of both proteins, which also found that ZFP36
binds with higher affinity to AU-rich sequences relative to
U-rich and CU-rich sequences, and vice versa for ELAVL1
[48,49].
Previously reported in vitro ZFP36 binding studies
quantified the binding of numerous RNA probes to the
73 amino acid portion of ZFP36 containing the TZF
using fluorescence anisotropy measurements [48]. For
each probe, we compared the experimentally determined
association, K, and disassociation constant, Kd, with the
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Figure 2 (See legend on next page.)
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Figure 2 ZFP36 binds to mRNAs encoding regulatory proteins. (A) Gene ontology enrichment analysis of genes with ZFP36 binding sites
ranked and shaded from red (lowest) to green (highest) by Bonferroni corrected P values (< 0.05) from Panther DB. (B) Distribution of ZFP36
binding sites (red) and ELAVL1 binding sites (purple) from PAR-CLIP data for immune-relevant RBPs. The genomic span is indicated for each gene
and these spans vary greatly. (C-F) Visualization of individual ZFP36 binding sites with the T-to-C conversion density estimate (red line) and read
counts (grey) within the ZFP36, ZFP36L1, ZFP36L2 and ELAVL1 3′ UTRs. chr, chromosome; PAR-CLIP, photoactivatable ribonucleoside cross-linking
and immunoprecipitation; RBP, RNA-binding protein; UTR, untranslated region.
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http://genomebiology.com/2014/15/1/R12SNR values calculated from our ZFP36 PAR-CLIP data
matching experimental RNA probe and in vivo binding
site sequences. We observed a very strong correlation with
Kd values (Figure 3C). This strong concordance allowed
us to calculate predicted Kd values from the PAR-CLIP
derived SNR ratios and thus perform in silico experimentsA
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main, a single nucleotide disruption by any nucleotide
resulted in similar increases in predicted Kd values.
However, multiple continuous disruptions with non-
uridylates exhibit quite large increases in predicted Kd
values, whereas disruptions with uridylates had little to no
change (Figure 3D). These results highlight the quality
and complementary value of the PAR-CLIP method, as
well as the detailed in vitro biochemical analysis of ZFP36
substrate specificity.
Specificity of ZFP36 function
To evaluate the regulatory function of ZFP36, we used
microarray analysis to compare transcript abundance be-
fore and after doxycycline-induction of EGFP-ZFP36 fu-
sion protein expression in HEK293 cells otherwise
expressing little endogenous ZFP36 (Additional file 4:
Figure S2A,B and Additional file 5: Table S2). We detected
2,784 genes with statistically significant expression differ-
ences by comparing overnight doxycycline-induced cells to
mock-induced cells. Doxycycline treatment of the parental
cell line did not yield any statistically significant differences
defined by Bonferroni corrected P < 0.01 (Additional file 4:
Figure S2C). Only 45% of the differentially expressed genes
decreased as a result of ZFP36 overexpression (downregu-
lated genes). The large number of upregulated genes
was likely due to secondary effects from prolonged ZFP36
overexpression (Additional file 4: Figure S2D). (Detailed
characterization of genes with ZFP36 and ELAVL1 sites
with numerous other motif contributions for signifi-
cantly upregulated and downregulated genes are shown
in Additional file 4: Figure S2H.) The 1,254 significantly
downregulated genes decreased by approximately 3.5 fold
on average. The breadth and degree of expression differ-
ences resulting from EGFP-ZFP36 overexpression were
distinctly greater than the typical fine-tuning associated
with most RBPs and miRNAs. This is particularly striking
in comparison to ELAVL1 where only 15 genes exhibited
greater than a twofold change due to ELAVL1 knockdown
(Additional file 4: Figure S2G from [25]).
Downregulated genes were significantly enriched for
AU-rich sequences in an unbiased analysis of the contribu-
tion of 3′ UTR motif elements to expression changes
(Additional file 4: Figure S2E) [50]. Thus, we examined
the association between the number of counts per 3′ UTR
of specific AREs and EGFP-ZFP36-induced changes in
mRNA abundance. The RREs described by the ZFP36L2:
ARE NMR structure, the UAUUUAUU octamer and the
UAUU half-site, had the strongest association with ZFP36-
induced changes in mRNA abundance. The UAUUUAUU
octamer had a stronger association with ZFP36-induced
changes in mRNA abundance than the UUAUUUAUU
nonamer (Additional file 4: Figure S2F). The UAUU
half-site had a stronger association with ZFP36-inducedchanges in mRNA abundance than the AUUUA pentamer
(Additional file 4: Figure S2F).
Among differentially expressed genes, those containing
ZFP36 sites were twice as often downregulated com-
pared to those not containing ZFP36 sites (Figure 4A).
Pathway enrichment analysis showed that downregulated
genes with ZFP36 sites were enriched in immune and in-
sulin signaling genes (Figure 4A). This is consistent with
early studies demonstrating ZFP36-dependent immune
system phenotypes as well as rapid insulin-stimulated
ZFP36 induction [10,11]. Recent studies have identified
that ZFP36 acts as a tumor suppressor in Myc-induced
lymphomas, in which Myc directly binds to an initiator
element downstream of the TATA box to suppress
ZFP36 transcription. The resulting deregulation of nu-
merous ARE-containing genes contributes to the devel-
opment and maintenance of the malignant state, which
can be abolished by restoring ZFP36 [51]. The top five
significantly enriched pathways were remarkably accur-
ate for the known physiological roles of ZFP36 and were
not enriched for ZFP36 target genes without significant
changes in expression.
To illustrate functional effects, genes are frequently
stratified by a variable of interest (such as the presence or
absence or number of binding sites), followed by a statis-
tical test for significant phenotypic differences (such as ex-
pression changes) between the subsets. For instance, we
observed strong associations between the number of
ZFP36 sites in the 3′ UTR of a gene and its downregula-
tion due to EGFP-ZFP36 overexpression (Figure 4B), be-
tween 3′ UTR length and EGFP-ZFP36-induced changes
in mRNA abundance (Figure 4C), and between ZFP36
sites and 3′ UTR length. These effects were corroborated
by the strength of Spearman correlations between all three
variables (Figure 4D, left). However, pairwise correlations
are not able to quantify direct and indirect relations for
more than two variables and thus we employed partial
correlation analysis. Comparing the correlation and partial
correlation of ZFP36 sites and 3′ UTR length with EGFP-
ZFP36-induced changes in mRNA abundance, most of the
relation between ZFP36 sites and EGFP-ZFP36-induced
changes in mRNA abundance was independent of 3′ UTR
length and vice versa (Figure 4D). Secondary effects from
prolonged ZFP36 overexpression, such as spontaneous
stress granule assembly [52] and changes in the expression
levels of other RBPs, were potential explanations for the
independent contribution of 3′ UTR length to EGFP-
ZFP36-induced changes in mRNA abundance.
We determined which transcript regions contained
the most independent information for explaining EGFP-
ZFP36-induced changes in mRNA abundance, without
having to lose statistical power by separating transcripts
into mutually exclusive categories, such as binding
within introns only or 3′ UTRs only. EGFP-ZFP36-
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Figure 4 (See legend on next page.)
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Figure 4 Functional sensitivity of ZFP36 sites. (A) Mosaic plot of significantly differentially upregulated (blue) and downregulated genes (pink)
with and without ZFP36 sites. Significantly enriched MSigDB canonical pathway gene sets for downregulated genes with ZFP36 sites (yellow
outline). Cumulative distribution function plots of EGFP-ZFP36-induced changes in mRNA abundance for 3′ UTRs grouped (B) by number of
ZFP36 sites and (C) by 3′ UTR length. For all correlation plots the color and shape of the node indicates specific data classes (circles: PAR-CLIP
sites, squares: expression change upon RBP perturbation, grey diamonds: transcript features, blue: ZFP36-related feature, purple: ELAVL1-related
feature). Edge line thicknesses are proportional to correlation coefficient strength and the direction of correlation is indicated by the sign and
color (negative in red and positive in green). (D) Correlation (left) and partial correlation (right) analysis of number of ZFP36 sites per 3′ UTR
(blue circles), EGFP-ZFP36-induced changes in mRNA abundance (blue squares) and 3′ UTR length for all genes. (E) Correlation (left) and partial
correlation (right) analysis of the number of ZFP36 sites per mRNA region and EGFP-ZFP36-induced changes in mRNA abundance for all genes
with at least one ZFP36 site. kb, kilobase; PAR-CLIP, photoactivatable ribonucleoside cross-linking and immunoprecipitation; TTP, tristetraprolin;
UTR, untranslated region; FDR, false discovery rate; LFC, log2 fold change; OE, overexpression; CDS, coding sequence.
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tively with the number of ZFP36 3′ UTR sites and
positively with the number of intronic ZFP36 sites
(Figure 4E, left). Partial correlation analysis revealed that
ZFP36 sites outside of 3′UTRs, including introns, did
not contribute any additional independent explanation
of EGFP-ZFP36-induced changes in mRNA abundance
(Figure 4E, right). Here, the strong negative association
or avoidance between the number of intronic and 3′
UTR sites per gene (like the results in Figure 1F) acts as
a mediator in explaining the spurious effects between in-
tronic ZFP36 sites and EGFP-ZFP36-induced changes in
mRNA abundance. This result does not rule out that
ZFP36 sites from other transcript regions have other
functional effects, but we only utilized 3′ UTR binding
sites for further analysis.
We compared our ZFP36 PAR-CLIP and overexpression
data from human HEK293 cells with global mRNA stability
changes after serum stimulation for ZFP36 wild-type (WT)
or knockout (KO) mouse fibroblast cell lines [53]. Genes
with increased mRNA half-lives in the ZFP36 KO vs WT
mouse cells were significantly enriched for genes with
ZFP36 PAR-CLIP sites in 3′ UTR (P = 0.003) and genes
significantly downregulated upon EGFP-ZFP36 overexpres-
sion (P = 0.001), but were not significantly enriched for
genes significantly upregulated upon EGFP-ZFP36 overex-
pression (P = 0.1) (Additional file 6: Figure S3A). Interest-
ingly, ELAVL1 RIP-chip targets from human Jurkat T-cell
activation were significantly enriched in genes with in-
creased mRNA half-lives in the ZFP36 KO vs WT
mouse cells, even though ZFP36 RIP-chip targets from
activated mouse macrophages were slightly but not sig-
nificantly enriched [18]. Genes with ELAVL1 sites in
the 3′ UTRs were similarly enriched, but genes without
ELAVL1 or ZFP36 sites in their 3′ UTR did not have
any enrichment. These results provide independent val-
idation of the ZFP36 bound and regulated genes in our
study using a system not reliant on ectopic overexpres-
sion of ZFP36. The enrichment of ELAVL1 gene is fur-
ther support for the potential of ELAVL1 to effect
expression of ZFP36 targets.Combinatorial regulation of mRNAs with AREs by ZFP36
and ELAVL1
As could be expected given the similarity in sequence
preferences, there was a substantial overlap of ZFP36
and ELAVL1 sites derived by PARalyzer from PAR-CLIP
data (Figure 5A and Additional file 7: Figure S4A). Spe-
cifically, over 84% of ZFP36 sites in the 3′ UTR over-
lapped an ELAVL1 site. Our ELAVL1 PAR-CLIP dataset
corresponded well at the site level and 3′ UTR level with
other ELAVL1 CLIP/PAR-CLIP data in HEK93 and
HeLa cell lines (Additional file 3: Figure S1E,F). Using
partial correlation analysis, we compared the independ-
ent contribution of the number of ZFP36 and ELAVL1
sites to EGFP-ZFP36-induced changes in mRNA abun-
dance, restricted to sites in the 3′ UTR since these
explained the vast majority of EGFP-ZFP36-induced
changes in mRNA abundance (Figure 4E and Additional
file 7: Figure S4B). After normalizing for differences in
library size, the number of ELAVL1 sites and the num-
ber of ZFP36 sites both correlated to a similar extent
with EGFP-ZFP36-induced changes in mRNA abun-
dance (Figure 5B; cf. also Additional file 7: Figure S4C).
Induction of EGFP-ZFP36 resulted in a 60% decrease in
ELAVL1 mRNA levels. This decrease in ELAVL1 mRNA
levels may explain some of the ability of ELAVL1 bind-
ing sites to explain ZFP36 overexpression changes. How-
ever, a previous study used a knockdown to reduce
ELAVL1 protein levels to 15%, and reported a much
smaller degree of expression changes (Additional file 4:
Figure S2G) compared to the EGFP-ZFP36-induced changes
in mRNA abundance [25]. Although we cannot rule out
non-linear effects from the combined increase in ZFP36
concentration and decrease in ELAVL1 concentration, the
data indicate that there is substantial potential for com-
binatorial regulation of ARE-containing mRNAs by ZFP36
and ELAVL1.
To assess specific sequences within ELAVL1-bound
sites and the strength of their contribution to the EGFP-
ZFP36-induced changes in mRNA abundance, we per-
formed the same analysis using ELAVL1 sites containing
CUUUC, UUUUU or AUUUA. The AUUUA ELAVL1
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Figure 5 ZFP36 and ELAVL1 combinatorial binding and regulation. (A) In 3′ UTRs, ZFP36 sites are much closer to ELAVL1 sites containing only
AUUUA (pink line) than to ELAVL1 sites containing only CUUUC (purple line). PUM2 (orange), FMR1 (green) and QKI (yellow) are included for reference. In
parentheses are the number of sites in the 200-nucleotide window, the number of 3′ UTRs with sites for both ZFP36 and the RBP and the number of
3′ UTRs with sites for the RBP. (B) Conditionally independent correlation between the number of ZFP36 binding sites, the depth normalized number of
ELAVL1best binding sites and EGFP-ZFP36-induced changes in mRNA abundance. (C, D) ELAVL1all binding sites containing AUUUA (and not UUUUU or
CUUUC) correlate independently at a higher level than ELAVL1all binding sites containing only CUUUC (and not UUUUU or AUUUA). (E) Motifs enriched in
overlapping ELAVL1 and ZFP36 binding sites vs motifs enriched in ELAVL1-specific binding sites. (F) Scatter plot of the mean and variance of EGFP-ZFP36-
induced changes in expression (on the y-axis, negative values indicate a reduction in EGFP-ZFP36 overexpression) and of ELAVL siRNA-knockdown-induced
changes in expression (on the x-axis, positive values indicate a reduction in ELAVL1 knockdown) for genes with both ELAVL1 and ZFP36 sites in the 3′ UTR
(red), genes with only ELAVL1 sites in the 3′ UTR (green), genes with neither ELAVL1 nor ZFP36 sites in the 3′ UTR (turquoise) and genes with only ZFP36
sites in the 3′ UTR (purple). The bars represent the variance and the point at which they cross the mean. Hotelling’s T2 score, calculated using the Hotelling R
package, and Bonferroni corrected P values are indicated for each category. RBP, RNA-binding protein; siRNA, small interfering RNA; UTR, untranslated region.
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changes in mRNA abundance than the CUUUC ELAVL1
sites (−0.07) (Figure 5C,D). This result was consistent with
the observation that ELAVL1 specific sites were character-
ized by predominantly U- and CU-rich sequences, while
overlapping ELAVL1 and ZFP36 sites were characterized
more by AU-rich sequences (Figure 5E). The exact same
analysis using an independently derived ELAVL1 HEK293
PAR-CLIP library yielded similar results (Additional file 7:
Figure S4D-F), supporting the robustness of our findings.
EGFP-ZFP36-induced changes in mRNA abundance
were better explained by the ARE nonamer and octamer
compared to U8 or U9. ELAVL1-knockdown-responsive
mRNAs had the reciprocal pattern (Additional file 6:
Figure S3B). Finally, transcripts containing 3′ UTR sites
for both ELAVL1 and ZFP36 had a greater concomitant
decrease upon ELAVL1 knockdown and decrease upon
ZFP36 overexpression, relative to transcripts containing
3′ UTR sites for only ELAVL1 or ZFP36 or no sites
(Figure 5F, shifted down and to the right). Taken together,
there is substantial potential for ZFP36 and ELAVL1 to
compete for the same pool of binding sites, while exerting
a more targeted influence on a subset of sites with factor-
specific sequence preferences.
Conclusions
Our global in vivo ZFP36–mRNA interaction experiments
support previously reported biochemical in vitro ZFP36
affinity measurements, demonstrating the remarkable pre-
cision and quantitative characteristics of ZFP36 PAR-CLIP
results. ZFP36 targets identified in this study were
enriched for ZFP36-dependent changes in mRNA stability
in mouse fibroblast cells. ZFP36 interacted with mRNAs
encoding proteins important for the immune response
and cancer. Many of these are other RBPs central to these
two biological processes, specifically other ARE-binding
RBPs such as the positive-stability regulator ELAVL1.
There was extensive overlap between the interaction sites
of ZFP36 and ELAVL1. Over 80% of ZFP36 sites in 3′
UTRs overlapped with ELAVL1 target sites. The prefer-
ence for ZFP36 and ELAVL1 to bind and regulate mRNAs
encoding RBPs suggests a complex interconnected net-
work of post-transcriptional regulation that needs to be
reconciled with respect to known ZFP36 and ELAVL1
protein expression, localization and modification dynam-
ics, particularly in response to immune activation [54].
Partial correlation analysis accounting for confounding
features demonstrated that a higher number of ZFP36 sites
corresponded to stronger downregulation upon EGFP-
ZFP36-induced changes in mRNA abundance. While the
two proteins bind AREs, ZFP36 clearly shows a preferences
towards AU- vs simply U-rich or CU-rich sequences rela-
tive to ELAVL1. This was corroborated at the level of
mRNA stability, since ELAVL1 sites containing AUUUAwere best able to explain EGFP-ZFP36-induced changes in
mRNA abundance.
In summary, this study provides a resource for the
precise transcriptome-wide RNA interactions of two
ARE-binding RBPs with antagonistic functions. The pre-
cise sequence definition and function of AREs are an im-
portant question that will greatly benefit from global
interaction data for these and other ARE-binding RBPs.
Furthermore, we have integrated multiple genome-wide
assays with computational analyses to advance our un-
derstanding of the sequence basis and extent of com-
binatorial gene regulation at the RNA level, in particular
the ARE-mediated regulation by two of the most well-
characterized RBPs.
Materials and methods
Cell lines
Doxycycline-inducible FLAG/HA-tagged ZFP36 HEK293
cell lines were produced utilizing the Flp-In™ T-REx™ 293
Cell Line system (Life Technologies, USA).
Flp-In™ T-REx™ HEK293 cells were generated with a
FLAG/HA-tagged human ZFP36 or an EGFP-tagged
human ZFP36. Both cell lines were cultured in DMEM
supplemented with 10% tetracycline-reduced fetal bo-
vine serum and appropriate selection antibiotics. For
induction of FLAG/HA-tagged or EGFP-tagged ZFP36
protein, cells were treated for 16 hr with 1 μg/ml doxy-
cycline (Sigma, USA).
PAR-CLIP
The protocol was performed as detailed in [41] for a
FLAG-HA-tagged ZFP36 and sequenced using an Illu-
mina platform. The primary dataset comprised previously
derived ELAVL1 PAR-CLIP and ELAVL1 knockdown data
[25]. This was integrated with ZFP36 PAR-CLIP data. An
independent ELAVL1 PAR-CLIP dataset for HEK293 cells
was also used to substantiate our results. Specifically, we
used the union of all ELAVL1 T1 PAR-CLIP libraries.
PUM2, QKI and FMR1 HEK293 PAR-CLIP libraries were
investigated to compare spatial binding biases in 3′ UTRs
[55,56]. Precise analysis parameters for the PAR-CLIP li-
braries above are provided in Additional file 1. Binding
site coordinates for ELAVL1 HEK293 CLIP and HeLa
PAR-CLIP were downloaded from doRiNA [57].
Briefly, reads from the ZFP36 and ELAVL1 deep-
sequencing library were stripped of the adaptor sequence
using Cutadapt [58]. Reads that were less than 20 nu-
cleotides in length or contained an ambiguous nucleo-
tide were discarded. The remaining reads were aligned
to the human genome (hg19), with up to one mismatch
allowed and ten alignment locations, with Bowtie version
0.12.7 [59]. Reads with T-to-C mismatches were recon-
ciled [42] to retain only those that mapped to a single gen-
omic location for the minimum number of mismatches.
Mukherjee et al. Genome Biology 2014, 15:R12 Page 12 of 16
http://genomebiology.com/2014/15/1/R12Annotation was performed as described in [56]. Full
site- and gene-level data for the primary data compared
are in Additional file 2: Table S1 and Additional file 5:
Table S2, respectively.
Motif affinity
The SNR values were calculated for each probe sequence
in Table one in [48] appearing at least once in 3′ UTR
ZFP36 binding sites. The SNR was calculated as in
[42], and is defined as the number of instances per nu-
cleotide in a given set of PARalyzer interaction sites, di-
vided by the number of instances per nucleotide in
the background set. In this case the background was
the sequence of the longest annotated 3′ UTR for
a gene. The SNR values were plotted against the K and
Kd values from [48]. The formula for the power curve
fit of the SNR to Kd was used to predict Kd values for
other sequences.
Microarray samples and analysis
EGFP-ZFP36 cells were passaged at 1:10 dilution in 15
ml of media in ten T75 flasks. They were allowed to
grow for three days to 60% confluence. They were then
treated with doxycycline (Sigma D989) to a final concen-
tration of 1 μg/ml. The same volume of sterile water was
used as a control. The cells were incubated for 16 hr at
37°C, in 5% CO2. The flasks without doxycycline were
about 80% confluent. Cells with doxycycline were about
40% confluent and there were more floating cells and
rounded cells. The cells were harvested by trypsinizing.
Cells from five flasks per treatment were pooled. They
were centrifuged at 500 g for 5 min, and resuspended
in growth medium to final concentrations of 1 × 107
cells/ml. Fluorescence-activated cell sorting (FACS) was
done using a FACSAria II from Becton Dickinson (San
Jose, CA). Cells were excited at 488 nm and sorted based
on their GFP fluorescence at 525/550 nm.
The FacsDiva software version 6.1.3 was used for ana-
lysis. Doublet discrimination gates were set on forward
scatter and side scatter to ensure the sorting of single
cells. The sort gate was set on a histogram of GFP + cells
for a fluorescence signal of greater than 103 log units.
Control cells were sorted in the same way, except that
fluorescent cells were excluded (Additional file 3: Figure
S1B). The sorted cells were collected into DMEM with
10% FBS in 6 ml polypropylene tubes at approximately
2 × 106 cells per tube. They were pelleted at 500 g for 20
min at 4°C and washed in PBS, then transferred into 1.5
microfuge tubes at approximately 4 × 106 cells per tube.
These were centrifuged at 500g for 20 to 30 min at 4°C.
The supernatant was removed, and the pellets were snap
frozen in liquid nitrogen and stored at −80°C. This ex-
periment was repeated on five independent days, using
cells from passages 17, 20, 23, 26 and 27. RNA wasisolated from approximately 3 × 106 to 6 × 106 cells using
the GE Illustra RNAspin mini kit. To control for doxy-
cycline effects, parental HEK293 cells were passaged at
1:4 or 1:5 dilution in 15 ml medium in four T75 flasks.
They grew for 2 days to approximately 60% confluence.
They were then treated with doxycycline in the same
way, that is, 1 μg/ml for 16 hr at 37°C in 5% CO2. Con-
trol cells were treated with the same volume of sterile
water. The cells were harvested by trypsinizing, and
processed and used for the microarray in the same way
as for the GFP + cells. The same experiment was per-
formed on five different days, and comparisons were
made using five doxycycline treated vs five vehicle
(water) treated samples, with each experiment done as
pairs of treated and untreated cells. The samples were
stored at −80°C. The integrity of the RNA was con-
firmed by running 3 μg of each RNA sample on 1.2%
agarose/formaldehyde gels.
Then 1.5 μg of RNA from each sample was provided
to the NIEHS Microarray Core Facility for analysis,
using an Affymetrix Human Genome U133 Plus 2.0 gene
chip (Affymetrix, Santa Clara, CA). As directed in the
Affymetrix 3′ IVT Express kit protocol, 100 ng of total
RNA was amplified. Then 12.5 μg of amplified biotin-
RNA was fragmented and 10 μg were hybridized to each
array for 16 hr at 45°C in a rotating hybridization oven
using the Affymetrix Eukaryotic Target Hybridization
Controls and protocol. Array slides were stained with
streptavidin/phycoerythrin utilizing a double-antibody
staining procedure and then washed for antibody ampli-
fication according to the GeneChip Hybridization, Wash
and Stain Kit and user manual. Arrays were scanned
in an Affymetrix Scanner 3000 and data were obtained
using the GeneChip® Command Console Software
(AGCC; Version 1.1). The data were normalized using
gcrma [60] and then filtered to retain only unambigu-
ously mapping probes and minimal expression level
(mean log hybridization value for replicates within a
group > 4.5). Bonferroni corrected P values for fold
changes were calculated using Gene Pattern [61]. Gene
set enrichment analysis [62] was used to compare
HEK293 data to ZFP36 mouse fibroblast mRNA stability
data. Human–mouse mappings were done using an ap-
propriate microarray chip. The probes were ranked by
differential mRNA half-life score, with higher scores in-
dicating a larger slope in ZFP36 KO than ZFP36 WT
cells (for details refer to [53]).
Partial correlation
Partial correlation analysis was performed using the R
package pcor.R with Spearman correlations coefficients
computed by the recursive formula [35]. Partial correl-
ation analysis measures the degree of association be-
tween tworandom variables, independent of some set of
Mukherjee et al. Genome Biology 2014, 15:R12 Page 13 of 16
http://genomebiology.com/2014/15/1/R12other random variables. Formally, the partial correlation,
ρXY Z, is defined as the correlation between the resid-
uals, RX and RY, found using linear regression of X with
Z and Y with Z where Z is the set of variables for which
we are controlling.
wX ¼ arg minw
XN
i¼1
xi− w;zih ið Þ2
( )
and
wY ¼ arg minw
XN
i¼1
yi− w;zih ið Þ2
( )
N is the number of variables in the set Z and 〈w, zi〉 is
the scalar product of the vectors w and zi. The residuals
can then be written as:
rX;i ¼ xi− wX;zi
 
rY ;i ¼ yi− wY;zi
 
From here, the partial correlation can be obtained
using the formula:
ρ^XY Z ¼ N∑
N
i¼1rX;irY ;i−∑
N
i¼1rX;i∑
N
i¼1rY ;iffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
N∑Ni¼1r
2
x;i− ∑
N
i−1rX;i
 2q ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
N∑Ni¼1r
2
Y ;i− ∑
N
i−1rY ;i
 2q
It is common to use a recursive algorithm utilizing the
reducibility of this nth-order formula to three (n – 1)th-
order partial correlations, represented by the formula:
ρXY Z ¼ ρXY Z = Z0f g−ρXY 0 Z = Z0f gρZ0Y Z = Z0f gffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1−ρ2X Z0 Z = Z0f g
q ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1−ρ2Z0 Y Z = Z0f g
q
X is the number of ELAVL 3′ UTR binding sites, Y is
the number of PUM2 3′ UTR binding sites and Z is
the log2 change in expression due to HuR knockdown.
The correlation analysis between these three variables
(Figure 6, left) shows there is a positive relation between
all three variables, which could lead one to believe
that PUM2 binding sites could explain changes in geneCorrelation
ELAVL1 
KD
ELAVL1 
PUM2 
Figure 6 Correlation vs partial correlation example. Correlation (left) an
(blue circle), ELAVL1 3′ UTR sites and ELAVL1-siRNA-induced changes in mR
untranslated region.expression upon HuR knockdown. However, the partial
correlation or the correlation between the residuals, RX
and RY (Figure 6, right), reveals that PUM2 binding sites
do not explain any additional changes in gene expression
upon HuR knockdown once HuR binding sites have
been accounted for. Accounting for such interdependen-
cies is clearly important for interpreting regulatory
mechanisms when integrating genomic datasets.
Analysis of spatial patterns
To visualize binding along transcripts, cluster data was
taken from PARalyzer output and annotated. Only 3′
UTR, 5′ UTR, coding and intron annotation categories
were utilized. The transcript segment associated with
the annotation category of each cluster was selected
using a GENCODE version 18 gene transfer format file
[63]. For each gene, we used the transcript that had the
longest segment matching the binding site of the cluster.
The location and relevant distance along the transcript
segment were then calculated. For each of the relevant
annotation categories, a density plot was created utiliz-
ing each of these distances. Permutations of the ob-
served data were used to create the background data
distributions. For each cluster we created a random site
along the length of its associated transcript segment re-
peated 100 times. The cluster plot function in the R LSD
package [64], was used to plot the observed and per-
muted data. The LSD cluster plot function creates a
graph in which the black center line is the median, and
the thick gray lines separating the color gradients
around the black line represent the upper and lower
quartiles. The color gradient continues until the 10th
and 90th percentiles.
Data availability
Both ZFP36 PAR-CLIP sequencing and overexpression
microarray datasets have been deposited into GEO
[GEO:GSE53185].Partial Correlation
ELAVL1 
KD
ELAVL1 
PUM2 
d partial correlation (right) analyses of number PUM2 sites per 3′ UTR
NA abundance (blue square). siRNA, small interfering RNA; UTR,
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Additional file 1: Analysis parameters. Precise analysis parameter files
for ZFP36 and ELAVL1 PAR-CLIP libraries.
Additional file 2: Table S1. Comma-separated values of ZFP36
PAR-CLIP binding sites.
Additional file 3: Figure S1. ZFP36 and ELAVL1 PAR-CLIP library
statistics. (A) Processing and summary statistics for reads and sites
identified by ZFP36 PAR-CLIP. (B) Bubble plot comparing number of
ZFP36 sites, the fraction of reads with a T-to-C conversion per cluster,
and conversion specificity, which is log10(#T-to-C reads/(1 + # reads with
conversions not T-to-C)). (C) Number of sites in mRNA regions for primary
libraries utilized (ZFP36 and ELAVL1). (D) Distribution of PAR-CLIP binding
sites in length-normalized 3′ UTRs for RBPs indicated by color with
the counts in parentheses. (E) Distance to other ELAVL1 3′ UTR sites.
(P) indicates the binding site coordinates were generated by our pipeline
and (d) indicates the binding site coordinates were downloaded from
doRiNA. PUM2 PAR-CLIP data, shown as a reference, from HEK293 cells.
For each library the numbers in parentheses are the number of sites
utilized in the plot, the total number of sites annotated as 3′ UTRs and
the total number of genes containing at least one 3′ UTR site. (F) Venn
diagram of the overlap of genes with 3′ UTRs with at least one binding
site for the libraries indicated. Primary ELAVL1 was the dataset used
throughout the current study.
Additional file 4: Figure S2. ZFP36 overexpression analysis.
(A) Western blot probed with monoclonal ZFP36 antibodies
demonstrating doxycycline-induced EGFP-ZFP36 expression (left two
lanes) and transfection of pBluescript (BS+) or ZFP36 cDNA plasmid into
HEK293 cells (right two lanes). (B) Fluorescence-activated cell sorting
(FACS) analysis of EGFP-ZFP36 expression treated with vehicle (above)
or doxycycline (below) see Materials and methods for details.
(C) Distribution of log2 fold change (left) and Bonferroni corrected
P values (right) for ZFP36 vs mock and doxycycline vs vehicle. (D) log2
fold change distribution of significantly differentially expressed genes
(P < 0.01). (E) Top enriched motifs identified by miREDUCE analysis of
ZFP36 overexpression. (F) Correlation between motif occurrence in 3′
UTR and ZFP36 overexpression. (G) log2 fold change distribution for
mock knockdown vs ELAVL1 knockdown. (H) Comparison between 3′
UTRs of transcripts significantly downregulated or upregulated upon
ZFP36 overexpression by categories defined by PAR-CLIP sites with
specific attributes indicated.
Additional file 5: Table S2. Comma-separated values of ZFP36
overexpression data and ZFP36 PAR-CLIP binding sites summarized at the
gene level.
Additional file 6: Figure S3. Comparison of ELAVL1 and ZFP36 targets
for ZFP36-deficient mRNA half-life data and known motifs. (A) Gene set
enrichment analysis (GSEA) results for mouse probes ranked by score
reflecting the differences in mRNA half-life between serum-stimulated
ZFP36 KO and WT mouse fibroblasts. Name of gene set indicates data
utilized, which included ZFP36 RNP immunoprecipitation-microarray
(RIP-chip) targets from activated mouse macrophage RAW cells and
ELAVL1 RIP-chip targets from a human Jurkat activation time course
[18,65]. The size, normalized enrichment score (NES) and multiple
hypothesis corrected significance value (FWER P-val) are indicated.
Colored bars within each column indicate the relative value. (B) Classical
ZFP36-targeted nonamers and octamers correlate more strongly with
ZFP36 overexpression than strings of Us of equivalent length. The
opposite relation was observed for ELAVL1 knockdown. (C) Gene
ontology enrichment analysis of genes with ZFP36 binding sites ranked
by Bonferroni corrected P values (< 0.05) from the Panther DB molecular
function category using the the differences in mRNA half-life scores as
expression ranks.
Additional file 7: Figure S4. Further relations for ELAVL1 and ZFP36
overexpression. (A) ZFP36 sites are closer to their nearest ELAVL1 sites
(blue line) than background simulations. (B) ELAVL1 binding sites in the
3′ UTR are far more highly correlated with ZFP36 overexpression than
those in the 5′ UTR, coding region or intron. (C) The number of ELAVL1all
binding sites correlates independently with ZFP36 overexpression at alevel much greater than the number of ZFP36 binding sites. Panels D,
E and F utilize independently derived HEK293 ELAVL1 PAR-CLIP data
from [26], which is colored a lighter purple. (D) The number of ELAVL1
binding sites found by Kishore et al. correlates independently with ZFP36
overexpression at a level much greater than the number of ZFP36
binding sites. (E, F) ELAVL1 binding sites found by Kishore et al.
containing AUUUA (and not UUUUU or CUUUC) correlate independently
at a higher level than ELAVL1 binding sites found by Kishroe et al.
containing only CUUUC (and not UUUUU or AUUUA).
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